Related Experiment Videos

Editorial: stepwise risk stratification for both F3 and F4 in NAFLD patients-authors' reply

Christian Labenz¹, Jörn M Schattenberg¹

¹Department of Internal Medicine I, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany.

Alimentary Pharmacology & Therapeutics

|November 30, 2018

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026.

Liver international : official journal of the International Association for the Study of the Liver·2026

Evaluation and management of heart failure patients with liver disease: European Journal of Heart Failure International Expert Position Paper.

European journal of heart failure·2026

Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset.

Alimentary pharmacology & therapeutics·2026

Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study.

Nature medicine·2026

Understanding the economic and healthcare burden of metabolic dysfunction-associated steatohepatitis: a real-world claims data analysis from Germany.

Journal of comparative effectiveness research·2026

Post-TIPS Dynamics of von Willebrand Factor for Risk Stratification After TIPS Placement.

Liver international : official journal of the International Association for the Study of the Liver·2026

See all related articles